Skip to main
ABBV
ABBV logo

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 36 analyst ratings
Buy
Strong Buy 28%
Buy 42%
Hold 28%
Sell 0%
Strong Sell 3%

Bulls say

AbbVie demonstrates a robust growth trajectory, with management projecting a high single-digit sales compound annual growth rate (CAGR) from 2024 to 2029, supported by strong sales expectations for Skyrizi and Rinvoq, which are anticipated to surpass $20 billion and $11 billion respectively by 2027. The company reported fourth-quarter 2024 sales of $15.1 billion, exceeding expectations primarily due to significant contributions from its immunology portfolio, which positions AbbVie favorably for continued growth in the near term. Additionally, the initial EPS guidance for 2025 is between $12.12 and $12.32, indicating solid profitability prospects as the company navigates its evolving product landscape.

Bears say

AbbVie's negative outlook is driven by several key risks, including disappointing commercial performance from crucial products like Skyrizi, Rinvoq, and Botox, which are essential for maintaining revenue stability. The anticipated market erosion of Humira due to the entry of biosimilars and slower than expected growth in key areas, such as inflammatory bowel disease, further complicate long-term revenue expectations. Additionally, macroeconomic challenges, particularly affecting the aesthetics sector, combined with potential pipeline setbacks, present significant headwinds that could hinder AbbVie's overall financial performance.

AbbVie (ABBV) has been analyzed by 36 analysts, with a consensus rating of Buy. 28% of analysts recommend a Strong Buy, 42% recommend Buy, 28% suggest Holding, 0% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 36 analysts, AbbVie (ABBV) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.